Press releases
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo Q1 2024 Interim Report
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
More ▼
Key statistics
As of last trade Orexo AB (0H19:LSE) traded at 20.78, -7.95% below its 52-week high of 22.58, set on May 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.40 |
---|---|
High | -- |
Low | -- |
Bid | 20.15 |
Offer | 22.25 |
Previous close | 20.78 |
Average volume | 528.63 |
---|---|
Shares outstanding | 34.71m |
Free float | 27.39m |
P/E (TTM) | -- |
Market cap | 737.60m SEK |
EPS (TTM) | -2.13 SEK |
Data delayed at least 20 minutes, as of May 20 2024 11:58 BST.
More ▼